American Association for Cancer Research
23266066cir180351-sup-202598_2_supp_5243362_pkcdcr.pdf (2.85 MB)

Figure S1-S8 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

Download (2.85 MB)
journal contribution
posted on 2023-04-03, 23:20 authored by Sarah E. Josefsson, Klaus Beiske, Yngvild N. Blaker, Mette S. Førsund, Harald Holte, Bjørn Østenstad, Eva Kimby, Hakan Köksal, Sébastien Wälchli, Baoyan Bai, Erlend B. Smeland, Ronald Levy, Arne Kolstad, Kanutte Huse, June H. Myklebust

Supplementary figures S1-S8.


Research Council of Norway

Norwegian Cancer Society



Checkpoint blockade can reverse T-cell exhaustion and promote antitumor responses. Although blocking the PD-1 pathway has been successful in Hodgkin lymphoma, response rates have been modest in B-cell non-Hodgkin lymphoma (NHL). Coblockade of checkpoint receptors may therefore be necessary to optimize antitumor T-cell responses. Here, characterization of coinhibitory receptor expression in intratumoral T cells from different NHL types identified TIGIT and PD-1 as frequently expressed coinhibitory receptors. Tumors from NHL patients were enriched in CD8+ and CD4+ T effector memory cells that displayed high coexpression of TIGIT and PD-1, and coexpression of these checkpoint receptors identified T cells with reduced production of IFNγ, TNFα, and IL2. The suppressed cytokine production could be improved upon in vitro culture in the absence of ligands. Whereas PD-L1 was expressed by macrophages, the TIGIT ligands CD155 and CD112 were expressed by lymphoma cells in 39% and 50% of DLBCL cases and in some mantle cell lymphoma cases, as well as by endothelium and follicular dendritic cells in all NHLs investigated. Collectively, our results show that TIGIT and PD-1 mark dysfunctional T cells and suggest that TIGIT and PD-1 coblockade should be further explored to elicit potent antitumor responses in patients with NHL.

Usage metrics

    Cancer Immunology Research



    Ref. manager